

S1 Table. Awake Micturition parameters (VSOP; N=6) in all treatment groups.

Intravesical Pretreat.	Intravesical Treat.	Volume (μ l)	Frequency (voids/3 hr)
<i>Acute BHA model</i>			
PBS	<i>Scrambled peptide</i>	158 \pm 13.6	3.7 \pm 0.4
PBS	<i>PAR₄-AP</i>	190 \pm 9.3	2.3 \pm 0.3
<i>MIF antagonism</i>			
mIgG1	<i>PAR₄-AP</i>	231 \pm 33.6	3.0 \pm 0.7
Anti-MIF mAb	<i>PAR₄-AP</i>	150 \pm 15.7	3.5 \pm 0.3
<i>CD74 antagonism</i>			
rIgG2b	<i>PAR₄-AP</i>	177 \pm 33.1	4.5 \pm 0.7
Anti-CD74 mAb	<i>PAR₄-AP</i>	118 \pm 18.0	5.5 \pm 0.5
Vehicle	<i>PAR₄-AP</i>	167 \pm 31.8	2.8 \pm 0.3
MIF098	<i>PAR₄-AP</i>	175 \pm 30.7	2.7 \pm 0.3
<i>CXCR₄ antagonism</i>			
AMD3100	<i>PAR₄-AP</i>	169 \pm 25.5	3.5 \pm 0.3
<i>CXCR₂ antagonism</i>			
0.1% DMSO	<i>PAR₄-AP</i>	177 \pm 26.3	3.2 \pm 0.3
SB225002	<i>PAR₄-AP</i>	192 \pm 62.0	3.5 \pm 0.8